Bicocca Open Archive

Logo unimib boa
FAGIUOLI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.029
EU - Europa 8.098
AS - Asia 5.730
SA - Sud America 422
AF - Africa 37
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 10
Totale 25.341
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.834
SG - Singapore 2.771
IE - Irlanda 1.756
HK - Hong Kong 1.754
IT - Italia 1.560
RU - Federazione Russa 1.509
DE - Germania 1.224
SE - Svezia 1.058
CN - Cina 652
BR - Brasile 357
IN - India 238
GB - Regno Unito 233
UA - Ucraina 201
CA - Canada 172
ID - Indonesia 122
NL - Olanda 89
AT - Austria 88
FI - Finlandia 87
FR - Francia 54
DK - Danimarca 53
VN - Vietnam 42
BE - Belgio 37
ES - Italia 27
TR - Turchia 27
CZ - Repubblica Ceca 26
AR - Argentina 18
PL - Polonia 18
IR - Iran 14
KR - Corea 14
EU - Europa 12
MX - Messico 12
PT - Portogallo 12
EC - Ecuador 11
RO - Romania 11
CL - Cile 10
JP - Giappone 10
CH - Svizzera 9
TW - Taiwan 9
EG - Egitto 8
UZ - Uzbekistan 8
BD - Bangladesh 7
CO - Colombia 7
PK - Pakistan 7
IQ - Iraq 6
NO - Norvegia 6
TN - Tunisia 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
AU - Australia 5
BG - Bulgaria 5
BO - Bolivia 5
GR - Grecia 5
KG - Kirghizistan 5
MA - Marocco 5
PE - Perù 5
PH - Filippine 5
AZ - Azerbaigian 4
EE - Estonia 4
LT - Lituania 4
MM - Myanmar 4
MY - Malesia 4
PA - Panama 4
SK - Slovacchia (Repubblica Slovacca) 4
TH - Thailandia 4
IL - Israele 3
JM - Giamaica 3
JO - Giordania 3
KE - Kenya 3
MD - Moldavia 3
NZ - Nuova Zelanda 3
PY - Paraguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BY - Bielorussia 2
DZ - Algeria 2
ET - Etiopia 2
GA - Gabon 2
HU - Ungheria 2
IM - Isola di Man 2
LK - Sri Lanka 2
LY - Libia 2
NP - Nepal 2
RS - Serbia 2
TO - Tonga 2
ZA - Sudafrica 2
A1 - Anonimo 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
HN - Honduras 1
HR - Croazia 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LU - Lussemburgo 1
Totale 25.333
Salva come PNG Salva come JPEG
Città #
Hong Kong 1.744
Singapore 1.734
Dublin 1.707
Ann Arbor 1.271
Frankfurt am Main 946
Princeton 886
New York 742
Ashburn 729
Fairfield 672
Chandler 662
Santa Clara 572
Woodbridge 462
Houston 439
Milan 398
Lawrence 327
Altamura 321
Wilmington 300
Cambridge 249
Seattle 241
Jacksonville 163
San Diego 160
Pune 156
Shanghai 155
Dearborn 143
Jakarta 117
Andover 89
Toronto 82
Rome 80
London 70
Nanjing 61
Nuremberg 61
Beijing 56
Los Angeles 54
Vienna 54
Washington 54
Helsinki 42
Hangzhou 40
Fremont 37
Guangzhou 36
Boardman 34
Council Bluffs 31
São Paulo 30
Bergamo 28
Lachine 28
Chicago 27
Brussels 26
Dallas 26
Ottawa 26
Shenyang 23
Tianjin 22
Huizen 20
Turin 20
Cedar Knolls 18
Dong Ket 18
Kilburn 17
Esslingen am Neckar 15
Lappeenranta 15
Monza 15
Brno 14
Catania 14
Jinan 14
Naples 14
Norwalk 14
Boston 13
Hyderabad 12
Manchester 12
Nanchang 12
Padova 12
San Mateo 12
Umeå 12
Belo Horizonte 11
Falls Church 11
Modena 11
Azzano San Paolo 10
Florence 10
Mountain View 10
Bologna 9
Brasília 9
Brescia 9
Groningen 9
Mumbai 9
Rio de Janeiro 9
Warsaw 9
Zhengzhou 9
Bonndorf 8
Changsha 8
Hounslow 8
Lisbon 8
Munich 8
The Dalles 8
Central 7
Hebei 7
Ningbo 7
Phoenix 7
Quito 7
Tashkent 7
Valencia 7
Albignasego 6
Assago 6
Nürnberg 6
Totale 16.956
Salva come PNG Salva come JPEG
Nome #
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 309
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 256
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 210
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 205
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 201
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 201
HCC persistence or recurrence after bridging therapy helps predict transplant list dropout and generate a more equitable exception policy 198
Health Related Quality of Life in the Major Liver Conditions 192
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 191
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 190
The impact of liver disease on the health-related quality of life 189
Health related quality of life in chronic liver diseases 189
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 185
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 182
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 182
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 182
High rates of 30-day mortality in patients with cirrhosis and COVID-19 182
Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases 179
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 176
Balancing donor and recipient risk factors in liver transplantation: The value of D-MELD with particular reference to HCV recipients 169
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 169
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis 168
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 168
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 167
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 166
A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list 159
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 158
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 158
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching 157
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 155
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study 155
Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria 151
Treatment of hepatocellular carcinoma: A cost analysis of yttrium-90 transarterial radioembolization versus sorafenib 151
Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and "silent hypoxemia" at admission: a severity-matched analysis 149
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients 145
Combined double lung-liver transplantation for cystic fibrosis without cardio-pulmonary by-pass. 144
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 144
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma 141
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS) 141
Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study 134
Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting 134
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 132
Successful pre- and posttransplant sofosbuvir-based anti-hepatitis C virus treatment in persons living with human immunodeficiency virus infection 132
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 132
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study 129
The SURF (Italian observational study for renal insufficiency evaluation in liver transplant recipients): A post-hoc between-sex analysis 127
A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study 126
Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study 125
Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients 122
COVID-19: role of resilience on the psychological impact of lockdown in liver transplant transitional candidates and recipients COVID-19: ruolo della resilienza sull’impatto psicologico del lockdown nei candidati e nei riceventi del trapianto di fegato (adolescenti-giovani adulti) 121
Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study 119
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 117
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 115
HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation 113
Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment in underserved patient populations because of mental health disorders, incarceration or homelessness 113
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 108
Open versus laparoscopic cholecystectomy in acute cholecystitis. Systematic review and meta-analysis 107
Safety and Efficacy of Subcutaneous Hepatitis B Immunoprophylaxis using “on demand” Approach: A Single Center Experience 106
Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients 105
COVID-19 in liver transplant candidates: Pretransplant and post-transplant outcomes - An ELITA/ELTR multicentre cohort study 105
Liver transplantation for HCV cirrhosis: Improved survival in recent years and increased severity of recurrent disease in female recipients: Results of a long term retrospective study 102
Selective use of ex-situ machine perfusion after normothermic regional perfusion in liver transplantation from donation after circulatory death 100
Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients 98
Citolisi e colestasi post-oltx per cirrosi HCV: l’enigma della diagnosi differenziale 98
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 96
Reply to: Correspondence on “High rates of 30-day mortality in patients with cirrhosis and COVID-19” 95
Bergamo and Covid-19: How the Dark Can Turn to Light 90
Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 (Leukemia, (2021), 35, 9, (2710-2714), 10.1038/s41375-021-01299-x) 89
The societal burden of chronic liver diseases: Results from the COME study 88
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 88
Location and allocation: inequity of access to liver transplantation for patients with severe acute‐on‐chronic liver failure in Europe 87
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 86
Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis 84
Safety and Efficacy of Subcutaneous Hepatitis B Immunoprophylaxis using" on demand" Approach: A Single Center Experience 81
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) 81
Physiological reno-portal bypass in liver transplantation with non-tumorous portal vein thrombosis 80
Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome 80
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments 79
Liver transplantation for hepatitis B virus-associated cirrhosis: a progress report 78
Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation 76
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 74
Safe pregnancy after liver transplantation: Evidence from a multicenter Italian collaborative study 74
Evidence for biliary epithelial to mesenchymal transition in human cholangiocarcinoma 74
Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis 72
Il nuovo immunodepressore FK 506 modula il danno acuto da D galattosamina nel ratto 71
The Role of Imaging in Portal Vein Thrombosis: From the Diagnosis to the Interventional Radiological Management 70
EVIDENCE FOR EPITHELIAL-MESENCHYMAL TRANSITION IN HUMAN CHOLANGIOCARCINOMA 70
α1-Antitrypsin Polymerizes in Alveolar Macrophages of Smokers With and Without α1-Antitrypsin Deficiency 70
The use of molecular assays in the management of viral hepatitis 70
Management of infections pre- and post-liver transplantation: report of an AISF consensus conference 70
Prevalent use of Combined Prophylaxis of Hepatitis B after liver transplantation in Italy: Results of a national survey in a large cohort 69
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation 68
Aumento di alfafetoproteina in pazienti con cirrosi HBeAg+/HBVDNA+ con sieroconversione ad anti HBe, spontanea ed indotta da interferon, 68
Plasma fibronectin in acute and chronic liver diseases [FIBRONECTINA PLASMATICA NELLE EPATOPATIE ACUTE E CRONICHE. VALIDITA DELL'ANALISI QUANTITATIVA] 68
The Italian data on SARS-CoV-2 infection in transplanted patients support an organ specific immune response in liver recipients 66
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 66
International liver transplantation society consensus statement on hepatitis c management in liver transplant candidates 66
Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis 66
Verso una modalità condivisa di profilassi post–olt con immunoglobuline antiepatite B 65
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 65
Totale 12.574
Salva come PNG Salva come JPEG
Categoria #
all - tutte 159.684
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 159.684
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020233 0 0 0 0 0 0 0 0 0 96 95 42
2020/20211.419 61 62 158 134 123 123 134 162 120 118 79 145
2021/20223.656 81 115 168 213 68 155 43 1.395 86 314 245 773
2022/20235.072 798 1.485 460 295 306 871 64 292 218 61 150 72
2023/20245.053 74 128 152 226 754 1.452 973 162 461 73 64 534
2024/20258.675 822 1.742 601 606 1.226 389 614 462 2.010 203 0 0
Totale 26.950